Axovant Sciences Ltd (NYSE:AXON) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

Several other research analysts also recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Axovant Sciences in a research note on Wednesday, September 27th. Jefferies Group LLC reiterated a “buy” rating and issued a $12.00 target price on shares of Axovant Sciences in a research note on Wednesday, September 27th. ValuEngine downgraded Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Evercore ISI reiterated an “outperform” rating and issued a $9.00 target price (down from $30.00) on shares of Axovant Sciences in a research note on Tuesday, September 26th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $25.00 target price (down from $30.00) on shares of Axovant Sciences in a research note on Tuesday, September 26th. Four research analysts have rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $14.68.

Axovant Sciences (NYSE AXON) opened at 7.73 on Thursday. Axovant Sciences has a one year low of $6.13 and a one year high of $27.98. The firm’s market capitalization is $831.17 million. The firm has a 50-day moving average price of $16.69 and a 200-day moving average price of $16.69.

Axovant Sciences (NYSE:AXON) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.12). Equities analysts anticipate that Axovant Sciences will post ($2.02) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Axovant Sciences Ltd (AXON) Stock Rating Upgraded by BidaskClub” was first reported by Marea Informative and is the property of of Marea Informative. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at http://www.mareainformativa.com/axovant-sciences-ltd-axon-stock-rating-upgraded-by-bidaskclub/116415/.

Institutional investors have recently bought and sold shares of the stock. Oppenheimer & Co. Inc. purchased a new stake in shares of Axovant Sciences in the first quarter valued at approximately $219,000. Federated Investors Inc. PA purchased a new stake in shares of Axovant Sciences in the second quarter valued at approximately $1,408,000. Tocqueville Asset Management L.P. purchased a new stake in shares of Axovant Sciences in the second quarter valued at approximately $375,000. Point72 Asset Management L.P. boosted its stake in shares of Axovant Sciences by 1,718.3% in the first quarter. Point72 Asset Management L.P. now owns 209,100 shares of the biotechnology company’s stock valued at $3,124,000 after buying an additional 197,600 shares in the last quarter. Finally, Primecap Management Co. CA boosted its stake in shares of Axovant Sciences by 300.1% in the first quarter. Primecap Management Co. CA now owns 2,878,930 shares of the biotechnology company’s stock valued at $43,011,000 after buying an additional 2,159,428 shares in the last quarter.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Stock Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related stocks with our FREE daily email newsletter.